Sales & Marketing News | pharmaphorum

News

BMS, J&J challenges to Medicare negotiations are thrown out

In another setback for the pharma industry, a US federal judge has rejected a bid to overturn the Medicare pricing negotiation brought by Bristol-Myers Squibb and Johnson

News

X4 Pharma gets first FDA okay for WHIM syndrome drug

Patients in the US with the ultra-rare disease WHIM syndrome now have their first approved treatment, after X4 Pharma’s Xolremdi was given a green light by the FDA.

News

J&J gets CHMP nod for Rybrevant in first-line lung cancer

Johnson & Johnson’s Rybrevant is on the brink of EU approval as a treatment for a subset of patients with newly diagnosed EGFR-positive lung cancer, after a recommenda

News

Pfizer offers warranty for new haemophilia B therapy Beqvez

Pfizer has said it will launch its just-approved haemophilia B gene therapy Beqvez with a warranty programme that will provide “greater certainty” to payers, after setting

News

Is pharma’s interest in orphan drugs waning?

For many years, orphan drugs for rare diseases have been a draw for pharma companies, offering high prices, swift regulatory reviews, and often extended marketing exclusiv

News

Alzheimer’s drug Leqembi moves forward, still in low gear

Biogen has given an update on the rollout of its Eisai-partnered Alzheimer’s disease therapy Leqembi alongside its first-quarter results, showing that while the drug’s tak

BMS, J&J challenges to Medicare negotiations are thrown out

X4 Pharma gets first FDA okay for WHIM syndrome drug

J&J gets CHMP nod for Rybrevant in first-line lung cancer

Pfizer offers warranty for new haemophilia B therapy Beqvez

Is pharma’s interest in orphan drugs waning?

Alzheimer’s drug Leqembi moves forward, still in low gear

Gilead strikes again, penning $5bn deal to buy Tubulis

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks